Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and PCV13 in Early-Stage High-Risk CLL/SLL
NCT01351896Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2011
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Proportion of Patients Who Achieve an Antibody Response at 1 month. Started Nov 2011; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01351896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01351896.